Navigation Links
Antioxidant may disrupt Alzheimer's disease process

Amsterdam, NL, April 10, 2012 Alzheimer's disease (AD) is now the sixth leading cause of death among Americans, affecting nearly 1 in 8 people over the age of 65. There is currently no treatment that alters the course of this disease. However, an increasing amount of evidence suggests that changes in the way the body handles iron and other metals like copper and zinc may start years before the onset of AD symptoms. A new study shows that reducing iron levels in blood plasma may protect the brain from changes related to AD.

In the current study a group of investigators from led by Dr. Othman Ghribi, PhD, Associate Professor, Department of Pharmacology, Physiology, and Therapeutics, University of North Dakota School of Medicine and Health Sciences, rabbits were fed a high-cholesterol diet which caused them to accumulate plaques of a small protein called beta-amyloid (Aβ). These plaques are toxic to neurons and central to the development of Alzheimer's disease. The rabbits also developed changes in tau protein, which is part of the skeleton of neurons. When this protein becomes heavily phosphorylated, the ability of neurons to conduct electrical signals is disrupted. Following treatment with a drug called deferiprone (an iron chelator), the iron level in the rabbits' blood plasma was reduced and the levels of both beta-amyloid and phosphorylated tau in the brain were returned to normal levels.

Another degenerative process in AD involves the production of reactive oxygen species (ROS) that can damage neurons in the brain. Deferiprone is also thought to suppress this reactive oxygen damage caused by free iron in the bloodstream, however in this study there was no difference in reactive oxygen species in the treated group. It appears that iron in the AD brain is located in the wrong places in particular it accumulates to very high levels in the cores of beta-amyloid plaques and is very reactive in this setting.

According to Dr. Ghribi, "Our data show that treatment with the iron chelator deferiprone opposes several pathological events induced by a cholesterol-enriched dietDeferiprone reduced the generation of Aβ and lowered levels of tau phosphorylation." While there was no effect on ROS levels, he comments that "It is possible that a higher dose of deferiprone, or combination therapy of deferiprone together with an antioxidant to prevent ROS generation would more-fully protect against the deleterious effects of cholesterol-enriched diet that are relevant to AD pathology."

Noted expert on metals metabolism research on AD Ashley Bush, MD, PhD, Mental Health Research Institute, Melbourne, Australia, adds that "this research highlights the role of metal ions as key modulators for the toxic interactions of risk factors for Alzheimer's disease, in this case cholesterol. Drugs targeting these metal interactions hold promise as disease-modifying agents."


Contact: Daphne Watrin
IOS Press

Related biology news :

1. Antioxidant has potential in the Alzheimers fight, UGA researchers find
2. Powerful antioxidant resveratrol prevents metabolic syndrome in lab tests: U of A study
3. Antioxidant spices reduce negative effects of high-fat meal
4. Antioxidant formula prior to radiation exposure may prevent DNA injury
5. Antioxidants in pregnancy prevent obesity in animal offspring
6. Preterm mothers milk contains less antioxidants than mothers completing their gestation
7. Jefferson researchers provide genetic evidence that antioxidants can help treat cancer
8. Roasting coffee beans a dark brown produces valued antioxidants: UBC food scientists
9. Concerns about the safety of certain healthful plant-based antioxidants
10. Polyphenol antioxidants inhibit iron absorption
11. Want to slow aging? New research suggests it takes more than antioxidants
Post Your Comments:
(Date:9/29/2015)... -- News facts: , ... , Minimized design shrinks PC footprint , ... embedded Fujitsu PalmSecure authentication enable enterprises to realize benefits ... that good things come in small packages, with the ... desktop and mobile portfolio. Featuring workplace design that favors ...
(Date:9/28/2015)... YORK , Sept. 28, 2015  The ... respiration rate and body temperature, is an essential ... can be indicators of deterioration in a patient,s ... hospital, vital signs are typically taken during routine ... hours. If a patient deteriorates between these observation ...
(Date:9/28/2015)... Synaptics Inc. (NASDAQ: SYNA ), the ... Lenovo has selected Synaptics , Natural ID ™ ... smartphone, the Vibe P1. The new Vibe P1 ... and provide swift access to applications and mobile payments ... FS4202 sensor solution utilizes AES256-bit encryption of the fingerprint ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... the United States , ... represents about 14% of all new cases of kidney cancer.   ... Canada and Europe .  PRCC represents ... --> Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces ... AB (publ) ("AstraZeneca") have completed enrolment in a global Phase II ...
(Date:10/12/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic, and the Dental sectors of healthcare, ... filed against the Company has been dismissed by the ... and CEO, stated, "As we suspected, this case was ...
(Date:10/12/2015)... 12, 2015 cell surface marker detection ... 2022, according to a new report by Grand View Research, ... in incidence of oncology diseases and other cell-associated disorders. ... to reach USD 6.49 billion by 2022, according to a ... demand can be attributed to rise in incidence of oncology ...
(Date:10/12/2015)... DIEGO , Oct. 12, 2015  Patara ... debilitating allergic and inflammatory diseases and conditions, today ... A preferred stock financing. Concurrent with the close ... entered into a Loan and Security Agreement with ... up to $7 million. Patara will use the ...
Breaking Biology Technology: